08049.HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.65
−1.85%Year over year
Reported trailing growth
- Revenue
- +19.7%
- EBITDA
- +56.0%
- EBIT
- +41.3%
- EPS
- +53.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2.3%
- EBITDA
- +8.3%
- EBIT
- +2.8%
- Net income
- +0.9%
- EPS
- +0.0%
- Free cash flow
- +16.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026